2 Postdoctoral Research Scientists

Starting Salary from £28,500 to £38,000 (depending on experience). Initial 3 year fixed term contract. Cancer Research UK Beatson Institute in Glasgow is one of Europe's leading cancer research centres. It supports cutting edge research into the molecular mechanisms of cancer development. The Institute provides an outstanding research environment, underpinned by state-of-the-art core services and advanced technologies. These posts are funded through a multi-faceted industrial collaboration investigating the role of RAC and RALGTPases in both CRC and PDAC. They will involve close interaction with team members across multiple sites. Prof Kurt I. Anderson: Imaging GTPase activation in cancer The Tumour Cell Migration Laboratory led by Professor Kurt I. Anderson has pioneered the use of imaging methods (FRAP and FLIM-FRET) to assess pharmacodynamics in vivo (Serrels et al. (2009) Cancer Res 69:2714; Timpson et al. (2011) Cancer Res 71:747; Nobis et al. (2013) Cancer Res 73:4674). We now seek a highly motivated and dedicated postdoctoral researcher to develop the use of FRET probes to read out GTPase activation in pancreatic cancer models. You will use imaging, molecular biology, and biochemical methods to optimize FRET probe performance, followed by use of the optimised probes to characterise mechanistic cancer models in vitro and in vivo. A relevant PhD is required and in depth knowledge of cancer biology and/or imaging would be advantageous. Informal enquiries or applications with covering letter, CV, and names of three referees should be sent to Prof Kurt I. Anderson, Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK or by email to k.anderson@beatson.gla.ac.uk Prof Owen Sansom: Testing the functional requirement for RAC and RAL signalling downstream of KRAS mutation in pancreatic and colon cancer KRAS is commonly mutated in both colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). KRAS mutation initiates nearly all PDAC whilst in CRC KRAS mutation occurs after APC mutation to drive progression. Although much work has concentrated on the MAPK and PI3-Kinase signalling pathways downstream of RAS activation, the work of our group (and others) suggest that both RAC and RAL are very important nodes (see Myant et al Cancer Cell 2013). You will use state of the art in vitro and in vivo modelling and imaging as well as established biochemistry and molecular biology. A relevant PhD is required and in depth knowledge of cancer biology and/or in vivo modelling would be advantageous. Informal enquiries or applications with covering letter, CV, and names of three referees should be sent to Prof Owen Sansom, Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK or by email to r.gebbie@beatson.gla.ac.uk Closing date for applications: 28th February 2014